Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.64 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.64 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.64 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.64 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.64 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280440 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL4880963 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL7129864 | 0.76 | CYP3A4 (0.66) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL24254524 | 0.76 | CYP3A4 (0.61) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL30565215 | 0.75 | PGR (0.75) | PGRBRD4ALDH1A1PKMHSD17B2 | |
| SCHEMBL1403074 | 0.75 | PGR (0.75) | PGRBRD4ALDH1A1PKMHSD17B2 | |
| SCHEMBL1489068 | 0.74 | PGR (0.65) | PGRBRD4ALDH1A1PKMHSD17B2 | |
| SCHEMBL22441735 | 0.74 | PGR (0.72) | PGRBRD4PKMHSD17B2MAPT | |
| SCHEMBL1859217 | 0.74 | PGR (0.68) | PGRBRD4ALDH1A1PKMHPGD | |
| SCHEMBL94971 | 0.74 | PGR (0.65) | PGRBRD4ALDH1A1PKMHSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | CYP3A4 950/4885CYP2D6 581/4885PSEN1 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.